Clinical Trial Update: Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating retreatment with thalidomide for vascular malformations in patients who failed the first course has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Bleeding of Unknown Origin
• Gastrointestinal Vascular Malformation

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Zhizheng Ge | Conditions: Gastrointestinal Bleeding of Unknown Origin, Gastrointestinal Vascular Malformation | Phase 2 | Status: WITHDRAWN